BIOMAT Database Logo BIOMAT Database Logo

Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2006

Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Department of Chemistry, Yale University, New Haven, CT 06520-8107, USA.

Following computational analyses, potential non-nucleoside inhibitors of HIV-1 reverse transcriptase have been pursued through synthesis and assaying for anti-viral activity. The general class Het-NH-Ph-U has been considered, where Het is an aromatic heterocycle and U is an unsaturated, hydrophobic group. Results for compounds with Het=2-thiazoyl and 2-pyrimidinyl are the focus of this report.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D006571 Heterocyclic Compounds Cyclic compounds that include atoms other than carbon in their ring structure. Heterocyclic Compound,Compound, Heterocyclic,Compounds, Heterocyclic
D000588 Amines A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) Amine
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D057927 Hydrophobic and Hydrophilic Interactions The thermodynamic interaction between a substance and WATER. Hydrophilic Interactions,Hydrophilic and Hydrophobic Interactions,Hydrophilicity,Hydrophobic Interactions,Hydrophobicity,Hydrophilic Interaction,Hydrophilicities,Hydrophobic Interaction,Hydrophobicities,Interaction, Hydrophilic,Interaction, Hydrophobic,Interactions, Hydrophilic,Interactions, Hydrophobic
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D024921 Drug Resistance, Multiple, Viral The ability of viruses to resist or to become tolerant to several structurally and functionally distinct drugs simultaneously. This resistance phenotype may be attributed to multiple gene mutation. Drug Resistance, Extensive, Viral,Drug Resistance, Extensively, Viral,Extensive Antiviral Drug Resistance,Extensively Antiviral Drug Resistance,Multidrug Resistance, Viral,Multiple Antiviral Drug Resistance,Resistance, Viral Multidrug,Viral Multidrug Resistance,Viral Multidrug Resistances

Related Publications

Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
April 2012, Bioorganic & medicinal chemistry letters,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Lead optimization of diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
June 2010, ChemMedChem,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
November 2006, Bioorganic & medicinal chemistry letters,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
February 2004, Journal of medicinal chemistry,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
August 2008, Bioorganic & medicinal chemistry letters,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.
December 2013, Future medicinal chemistry,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Structure-directed linker optimization of novel HEPTs as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
April 2023, Bioorganic chemistry,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
February 2013, Bioorganic & medicinal chemistry letters,
Juliana Ruiz-Caro, and Aravind Basavapathruni, and Joseph T Kim, and Christopher M Bailey, and Ligong Wang, and Karen S Anderson, and Andrew D Hamilton, and William L Jorgensen
Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
August 2014, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!